Clinical Trials · NCT03386162
SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- UNICANCER
- Enrollment
- 31
- Start date
- Mar 2018
- Locations
- 14 sites, France
- Primary endpoint
- progression-free survival